Studies of fasting-mimicking diet in people
36 studies gave fasting-mimicking diet to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases glucose4.7 mmol/L to 4.0 mmol/L down: Decreases IGF-123 nmol/L to 17.9 nmol/L up: Increases ketonenear zero to median 1.86 mmol/L | Trialtwo cycles of a 4-day FMD separated by 3 weeks of regular diet | 9 peopleHealthy volunteers | Nutrients, Aug 3, 2026 |
down: Decreases left ventricular massmean difference, -5.47 g up: Improves early-to-late peak filling ratiomean difference, 0.27 up: Improves mitral annular early peak velocitymean difference, 0.84 cm/sec | Randomized trial6 months | 82 peopleBothmean age, 62.9 years ± 8.5Older adults; in individuals with type 2 diabetes | Radiology. Cardiothoracic imaging, Jul 30, 2026 |
up: Improves clinical response69.2% FMD versus 43.8% control up: Improves clinical remission64.6% FMD versus 37.5% control down: Decreases calprotectin−22.0% versus 8.0% | Randomized trialthree months | 97 peoplemedian age 45.0 years (IQR 35.0 to 55.0)Patients with mild-to-moderate Crohn's disease | Nature medicine, Jan 13, 2026 |
down: Decreases body weight down: Decreases fasting glucose down: Decreases HOMA-IR | Randomized trial8 days | 30 people83.3% were femalemean age of 49.1 ± 11.8 yearsParticipants recruited from the San Antonio, Texas USA community | GeroScience, Dec 11, 2025 |
no change: Has no effect on quality of lifeunadjusted mean difference −0.04, 95% CI −0.10 to 0.03 | Randomized trialone year | 92 peoplePatients with type 2 diabetes | BMC primary care, Nov 10, 2025 |
down: Decreases IGF-1 down: Decreases body mass-2.04 ± 0.42 kg [-2.86, -1.21 kg] down: Decreases fat mass | Trialthree cycles of the 5-day FMD | 30 peoplefemale genderaged ≥ 18 yearsPatients with histologically confirmed invasive breast cancer scheduled to receive chemotherapy | Breast cancer research and treatment, Jul 25, 2025 |
down: Decreases abdominal visceral adipose tissue-37.9 cm2 (95 % CI -54.7, to -21.0) down: Decreases abdominal subcutaneous adipose tissue-20.9 cm2 (95 %CI -34.5 to -7.3) no change: Has no effect on abdominal muscle area-1.6 cm2 (95 % CI -4.6 to 1.4) | Randomized trial12 months | 89 peoplePatient cohorts | Nutrition, metabolism, and cardiovascular diseases : NMCD, Apr 30, 2025 |
down: Decreases C-reactive protein-0.20 ± 0.30 mg/l vs -0.11 ± 0.52 mg/l (p = 0.632) | Randomized trial3 months | 19 peoplePost-non-surgical periodontal therapy | Journal of dentistry, Feb 19, 2025 |
down: Decreases proton density fat fraction-2.8 %, 95 % CI -4.7 to -0.8 down: Decreases iron content corrected T1-29.9 ms, 95 % CI -51.8 to -8.0 | Randomized trial12 months | 89 peopleType 2 diabetes | Clinical nutrition (Edinburgh, Scotland), Feb 18, 2025 |
up: Improves chemosensory function down: Decreases hyposmia5.9-fold decrease, from 38.1% to 6.4% | Randomized trial5 consecutive days each month for 6 months | 102 people58 females out of 113 enrolled53.1 ± 12.3 yearsCaucasian adults with BMI ≥25 | Cell reports. Medicine, Feb 18, 2025 |
down: Decreases myocardial triglyceride content-0.235 % MTGC, p = 0.027 | Randomized trial12-month | 100 peopleType 2 diabetes | Nutrition, metabolism, and cardiovascular diseases : NMCD, Jan 9, 2025 |
down: Decreases body weight up: Increases L-glutamine | Treated cohort | bioRxiv (Cold Spring Harbor Laboratory), Dec 30, 2024 | |
down: Decreases grade III vomiting down: Lowers the risk of neutropenia down: Decreases IGF-1 | Randomized trial3 days before to and on the day of each cycle of chemotherapy | 44 peopleaged between 35 and 68 yearsRecently diagnosed HER-2 negative BC patients | Frontiers in nutrition, Dec 4, 2024 |
down: Decreases proteinuria up: Improves endothelial function | Trial3 months | In patients with chronic kidney disease | Science translational medicine, Oct 30, 2024 |
no change: Has no effect on diet quality up: Increases physical activity34.6 to 38.5 h/wk vs 34.9 to 29.0 h/wk, p = 0.03 | Randomized trialone year | 92 peopleaged > 18 years and < 75 yearsPatients diagnosed with type 2 diabetes with BMI ≥ 27 kg/m2 | BMC primary care, May 2, 2024 |
down: Decreases medication effect score−0.3 (95% CI −0.4, −0.2) down: Decreases HbA1c−3.2 mmol/mol (95% CI −8.0, −2.0) up: Improves glycaemic management53% vs 8% | Randomized trial12 months | 100 people>18 years and <75 yearsIndividuals with type 2 diabetes and BMI ≥27 kg/m2 | Diabetologia, Mar 28, 2024 |
down: Decreases biological age-2.5 years down: Decreases insulin resistance1.473 ± 0.85 to 1.209 ± 0.99 down: Decreases hepatic fat | Randomized trialthree cycles of this 5-day FMD | 100 people18 to 70 years of ageGenerally healthy adult volunteers without a diagnosed medical condition in the previous 6 months | Nature communications, Feb 20, 2024 |
down: Decreases reactive hyperemia index−0.4 in FMD vs not in MD down: Decreases PULS cardiac test scoreFMD: −1.5 (p = 0.0224) vs. MD: −2.3 (p = 0.0390) | Randomized trial4 months | 84 peopleThe FMD arm included 32 females versus 20 in the MD armover the age of 35 to 75 yearsSubjects of both sexes over the age of 35 to 75 years | npj metabolic health and disease, Dec 13, 2023 |
up: Extends lifespan overall survivalHR 0.40, 95% CI 0.19-0.86 | Treated cohort | Patient cohorts | International journal of cancer, Aug 24, 2023 |
| Randomized trial71 days | 45 peoplefemale participantsranging in age from 35 to 60 years oldFemale participants in good general health and social well-being with mild to moderate scores for parameters on the global face | Journal of clinical medicine, Feb 21, 2023 | |
up: Improves quality of lifep < 0.05 up: Improves sleep qualityp < 0.05 down: Decreases body weightconsiderably reduced | Randomized trialtwo months | 62 peopleMen50-60 years oldMidlife adults; obesity hypoventilation syndrome | Journal of complementary & integrative medicine, Sep 30, 2022 |
no change: Has no effect on albumin-to-creatinine ratio110.3 (99.2, 121.5) mg/g, P = 0.45 down: Decreases albumin-to-creatinine ratio−30.3 (−35.7, −24.9) mg/g, P ≤ 0.05 down: Decreases HOMA-IR−3.8 (−5.6, −2.0), P ≤ 0.05 | Randomized trial6 diet cycles | 41 people50 to 75 yearsPatients with type 2 diabetes with good glycemic and blood pressure control, optimized treatment, and increased ACR | The Journal of clinical endocrinology and metabolism, Jun 7, 2022 |
down: Decreases body weight-3.79 kg (95% CI 1.97–5.61 kg) down: Decreases abdominal circumference-4.57 cm down: Decreases systolic blood pressure-9.52 mmHg | Trial3 cycles of a 4-day diet | 35 peoplemenProspective group of men with prostate cancer treated in a community oncology setting | Prostate cancer and prostatic diseases, Mar 21, 2022 |
down: Decreases trimethylamine N-oxide down: Decreases body weight down: Decreases IGF-1-37 ± 8 ng/mL | Trial5 days | 44 peopleGenerally healthy omnivorous volunteers | Nutrients, Mar 5, 2022 |
down: Decreases body mass-2.6 kg no change: Has no effect on muscle strength no change: Has no effect on muscle volume | Randomized trial1 cycle | 24 peopleMen | European journal of applied physiology, Jan 16, 2022 |
down: Decreases albumin-to-creatinine ratio-30.3 mg/g (95% CI -35.7, -24.9 mg/g; P≤0.05) down: Decreases HOMA-IR-3.8 (95% CI -5.6, -2.0; P≤0.05) | Randomized trialsix months | 40 peopleIn patients with microalbuminuria | medRxiv, Dec 5, 2021 |
down: Decreases glucose down: Decreases regulatory T cells | Trial5-day | 101 peoplePatient cohorts | Cancer discovery, Nov 17, 2021 |
no change: Has no effect on body weight down: Decreases fat mass down: Decreases IGF-1 | Trial2 to 21 FMD cycles (average: 6.3 cycles per patient) | 90 people86% were females50.4 ± 8 years (range 19–72)Cancer patients with solid or hematological tumors undergoing active treatment | Cancers, Aug 9, 2021 |
no change: Has no effect on body weight-2.29 (1.95) kg vs -1.13 (2.27) kg, p = 0.06 down: Decreases fat mass up: Improves muscle mass | Randomized trial2 months | 60 peopleWomen18-55 yearsMetabolically healthy women with obesity | Obesity surgery, Jan 9, 2021 |
down: Decreases HbA1c6.47 ± 0.51% vs 7.50 ± 0.50% down: Decreases body mass index up: Increases high-density lipoprotein cholesterol2.28 ± 0.50 vs 1.42 ± 0.27 mmol/L | Randomized trial4-month | 115 people18–65 yearsPatients with type 2 diabetes and BMI ≥ 28 kg/m2 | Oxidative medicine and cellular longevity, Dec 5, 2020 |
up: Improves physical function down: Decreases symptoms | Randomized trial4-day | 131 peoplewomenWomen with HER2-negative breast cancer | Breast cancer research and treatment, Nov 11, 2020 |
no change: Has no effect on toxicity up: Increases radiologically complete or partial responseOR 3.168, P = 0.039 up: Increases pathological responseOR 4.109, P = 0.016 | Randomized trial3 days prior to and during neoadjuvant chemotherapy | 131 peopleWomenNeoadjuvant chemotherapy | Nature communications, Jun 23, 2020 |
up: Improves psychological quality of life down: Decreases body mass index | Randomized trial | 20 peopleIn patients with depression undergoing functional therapy | Journal of clinical psychology, May 11, 2020 |
no change: Has no effect on patient-reported outcomes | Randomized trial24 or 48 weeks | 90 peopleIntention-to-treat analysis | Multiple sclerosis and related disorders, May 6, 2020 |
down: Decreases body weight down: Decreases blood pressure-4.5 ± 6.0 mmHg down: Decreases IGF-1-21.7 ± 46.2 ng/ml | Randomized trial3 months | 100 people18 to 70 years of ageGenerally healthy adult volunteers | Science translational medicine, Feb 15, 2017 |
down: Decreases fasting blood glucose-5.9 ± 2.1% down: Decreases IGF-I~-15% down: Decreases body weight-3.1 ± 0.3% | Randomized trial3 months | 19 people18–70 years of ageGenerally healthy adults | Cell metabolism, Jun 18, 2015 |